{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/SGIOF/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-19T09:01:24.788Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":13376,"canonical_name":"SHIONOGI & CO LTD","cik":"0001281721","uei":null,"lei":null,"duns":null,"ticker":"SGIOF"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"clinical":9},"count":9,"timeline":[{"ts":"2026-10-09","kind":"clinical.trial","reporter":"Shionogi","title":"A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07743580","excerpt":"[\"SARS-CoV-2\"]","importance":60},{"ts":"2026-10-05","kind":"clinical.trial","reporter":"Shionogi","title":"Study of Sulthiame (S-054502) in Participants With Renal Impairment and Matched Healthy Controls","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07857837","excerpt":"[\"Renal Impairment\"]","importance":30},{"ts":"2026-09-02","kind":"clinical.trial","reporter":"Shionogi","title":"Study of Secutrelvir in Participants With COVID-19","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07746544","excerpt":"[\"COVID-19\"]","importance":60},{"ts":"2026-08-26","kind":"clinical.trial","reporter":"Shionogi","title":"A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07787650","excerpt":"[\"Pompe Disease\"]","importance":30},{"ts":"2026-08-06","kind":"clinical.trial","reporter":"Shionogi","title":"An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD)","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07750990","excerpt":"[\"Pompe Disease\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Shionogi","title":"A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05953480","excerpt":"[\"Acute Ischemic Stroke\"]","importance":45},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Shionogi","title":"Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06776432","excerpt":"[\"Sleep Apnea\"]","importance":45},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Shionogi","title":"Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD)","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07123155","excerpt":"[\"Pompe Disease\"]","importance":45},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Shionogi","title":"Safety and Pharmacokinetics Study of Naldemedine in Paediatric Participants Receiving Opioids","security_title":"PHASE1,PHASE2","status":"RECRUITING","accession_number":"NCT05588323","excerpt":"[\"Opioid-Induced Constipation (OIC)\"]","importance":45}]}